UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
RALEIGH, N.C., March 06, 2018 -- Syneos HealthTM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the Barclays Global Healthcare Conference in Miami. Mr. Macdonald’s presentation is scheduled for Tuesday, March 13, 2018, at 8:00 a.m. EDT.
Links to Syneos Health’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit syneoshealth.com.
Contacts
Investor Relations:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
[email protected]
Press/Media:
Danielle DeForge
Senior Director, External Communications
+1 202 210 5992
[email protected]
